Sell-the-news drop
Lilly is selling off violently despite strong EloraTZP weight-loss trial data, a classic sell-the-news reaction, with positive obesity data from rival Viking intensifying competitive fears in the GLP-1 market.
Sources: https://www.bloomberg.com/news/articles/2026-09-30/lilly-drug-combo-spurs-record-weight-loss-in-diabetes-study, https://www.reuters.com/lega
Sources
Ezbrisk weighs each event against the market reaction and publishes a verdict with an overreaction reading. How the methodology works